Access

Article

Nature Medicine 11, 623 - 629 (2005)
Published online: 15 May 2005 | doi:10.1038/nm1249

Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target

Roberto Chiarle1,2, William J Simmons1, Honjying Cai1, Girish Dhall1,3, Alberto Zamo4, Regina Raz1, James G Karras5, David E Levy1 & Giorgio Inghirami1,2

Anaplastic large cell lymphomas (ALCLs) are caused by chromosomal translocations that juxtapose the anaplastic lymphoma kinase (ALK) proto-oncogene to a dimerization partner, resulting in constitutive expression of ALK and ALK tyrosine kinase activity. One substrate of activated ALK in human ALCLs is the transcription factor Stat3, and its phosphorylation is accurately recapitulated in a new nucleophosmin (NPM)-ALK transgenic mouse model of lymphomagenesis. Here we show by gene targeting that Stat3 is required for the transformation of mouse embryonic fibroblasts in vitro, for the development of B-cell lymphoma in transgenic mice and for the growth and survival of both human and mouse NPM-ALK–transformed B and T cells. Ablation of Stat3 expression by antisense oligonucleotides significantly (P < 0.0001) impaired the growth of human and mouse NPM-ALK tumors in vivo. Pharmacological ablation of Stat3 represents a new candidate approach for the treatment of human lymphoma.

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.

NEWS AND VIEWS

Validating Stat3 in cancer therapy

Nature Medicine News and Views (01 Jun 2005)

An enriched look at tyrosine phosphorylation

Nature Biotechnology News and Views (01 Jan 2005)

RESEARCH

Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo ? use of the human tyrosinase promoter with human enhancers

Cancer Gene Therapy Original Article

The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination

Nature Medicine Letter (01 Jun 2008)

See all 56 matches for Research
$rb.Type.Code